Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × durvalumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

OTHER 9 INDUSTRY 6 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Tumor-Agnostic 1 Sarcoma 1 Lymphoid 1 Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1

Interventions

Cyclophosphamide 11 Rituximab 9 fludarabine 5 Prednisone 5 Vinorelbine 4 Vincristine 4 Epirubicin 4 zanubrutinib 3 Nivolumab 3 Gemcitabine 3 Drug Therapy 3 pegylated granulocyte colony-stimulating factor 2 fludarabine phosphate 2 Thiotepa 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Metformin 2 Ifosfamide 2 Granulocyte Colony-Stimulating Factor 2 Etoposide 2 Doxorubicin 2 Cytarabine 2 Bortezomib 2 treosulfan 1 plerixafor 1 pegfilgrastim 1 obinutuzumab 1 nilotinib 1 liposomal doxorubicin 1 ivarmacitinib 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03610061 2024-04-12

RaDD

Austin Health

Phase 1 Completed

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡